ACRO BIOMEDICAL CO., LTD. (ACBM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 3M 6M 9M Q3 '18: 8M Q4 '18: 7.9M Q1 '19: 6M Q2 '19: 3.8M Q3 '19: 1.4M Q4 '19: 193.5K Q1 '20: 881.5K Q2 '20: 881.5K Q3 '20: 881.5K Q4 '20: 688K Q1 '21: 99.5K Q2 '21: 599.5K Q3 '21: 599.5K Q4 '21: 1.2M Q1 '22: 1.4M Q2 '22: 896.5K Q3 '22: 896.5K Q4 '22: 658.5K Q1 '23: 360K Q2 '23: 360K Q3 '23: 360K Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

0 300K 600K 900K Q3 '18: 833.4K Q4 '18: 824.3K Q1 '19: 627.9K Q2 '19: 388K Q3 '19: 135.4K Q4 '19: 12.1K Q1 '20: 171.5K Q2 '20: 171.5K Q3 '20: 171.5K Q4 '20: 159.4K Q1 '21: 29.5K Q2 '21: 109.5K Q3 '21: 109.5K Q4 '21: 259.5K Q1 '22: 306.5K Q2 '22: 226.5K Q3 '22: 226.5K Q4 '22: 140.5K Q1 '23: 64K Q2 '23: 64K Q3 '23: 64K Q4 '23: 0 Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Income TTM

-18M -12M -6M 0 6M 12M 18M Q1 '17: 33.7K Q2 '17: 39K Q3 '18: 515.5K Q4 '18: 341.1K Q1 '19: 28.3K Q2 '19: -216K Q3 '19: -441.6K Q4 '19: -422.8K Q1 '20: -126.4K Q2 '20: -121.1K Q3 '20: -128.2K Q4 '20: -130.5K Q1 '21: -269K Q2 '21: -999.6K Q3 '21: -3.9M Q4 '21: -7.7M Q1 '22: -11.6M Q2 '22: -14.8M Q3 '22: -15.8M Q4 '22: -15.9M Q1 '23: -15.9M Q2 '23: -15.1M Q3 '23: -12.7M Q4 '23: -8.8M Q1 '24: -4.8M Q2 '24: -1.6M Q3 '24: -45.9K Q4 '24: -38K Q1 '25: -36.6K Q2 '25: -41.1K Q3 '25: -147.1K Q4 '25: -154K Q1 '26: -205.4K Q2 '26: -209.3K Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-18M -12M -6M 0 6M 12M 18M Q4 '15: -16.2K Q1 '16: -22.5K Q2 '16: -39.6K Q3 '16: -43.4K Q4 '16: -37K Q1 '17: -53.1K Q2 '17: -47.9K Q3 '18: 419.7K Q4 '18: 264.4K Q1 '19: 25.2K Q2 '19: -141.9K Q3 '19: -370.7K Q4 '19: -371.6K Q1 '20: -120.7K Q2 '20: -133.6K Q3 '20: -131.6K Q4 '20: -117.5K Q1 '21: -258.1K Q2 '21: -989.1K Q3 '21: -3.9M Q4 '21: -7.7M Q1 '22: -11.6M Q2 '22: -14.8M Q3 '22: -15.8M Q4 '22: -15.9M Q1 '23: -15.9M Q2 '23: -15.1M Q3 '23: -12.7M Q4 '23: -8.8M Q1 '24: -4.8M Q2 '24: -1.6M Q3 '24: -49.9K Q4 '24: -42.3K Q1 '25: -41.3K Q2 '25: -46.8K Q3 '25: -154.3K Q4 '25: -101.1K Q1 '26: -134.6K Q2 '26: -140.4K Q3 '16 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 2.5M 5M 7.5M Q3 '18: 7.2M Q4 '18: 7.1M Q1 '19: 5.3M Q2 '19: 3.4M Q3 '19: 1.2M Q4 '19: 181.4K Q1 '20: 710K Q2 '20: 710K Q3 '20: 710K Q4 '20: 528.6K Q1 '21: 70K Q2 '21: 490K Q3 '21: 490K Q4 '21: 938K Q1 '22: 1.1M Q2 '22: 670K Q3 '22: 670K Q4 '22: 518K Q1 '23: 296K Q2 '23: 296K Q3 '23: 296K Q4 '23: 0 Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Cash Flow TTM

-600K -400K -200K 0 200K 400K 600K Q1 '16: -23.3K Q2 '16: -26.7K Q3 '16: -34.7K Q4 '16: -23.5K Q1 '17: -44.8K Q2 '17: -56.8K Q3 '17: -463.3K Q4 '17: -496.5K Q1 '18: -57.6K Q2 '18: -552.4K Q3 '19: 79.7K Q4 '19: -59.7K Q1 '20: -33.4K Q2 '20: -20K Q3 '20: -127.5K Q4 '20: -199.5K Q1 '21: -181.8K Q2 '21: 322.8K Q3 '21: 322.8K Q4 '21: 299.3K Q1 '22: 569.8K Q2 '22: -208.7K Q3 '22: -197.4K Q4 '22: -147.5K Q1 '23: -415.2K Q2 '23: -67.2K Q3 '23: -13.4K Q4 '23: -15.4K Q1 '24: -23.4K Q2 '24: -32K Q3 '24: -38.8K Q4 '24: -36.7K Q1 '25: -45.7K Q2 '25: -133.4K Q3 '25: -181.4K Q4 '25: -196.3K Q1 '26: -223.6K Q2 '26: -140.1K Q3 '16 Q4 '17 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 25M 50M 75M Q3 '22: 60M Q1 '23: 60M Q2 '23: 60M Q3 '23: 60M Q1 '24: 60M Q2 '24: 60M Q3 '24: 60M Q1 '25: 60M Q2 '25: 60M Q3 '25: 60M Q1 '26: 60M Q2 '26: 60M Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.27 -0.18 -0.09 0.00 0.09 0.18 0.27 Q4 '15: 0.00 Q1 '16: 0.00 Q2 '16: 0.00 Q3 '16: 0.00 Q4 '16: 0.00 Q1 '17: 0.00 Q2 '17: 0.00 Q3 '17: 0.00 Q4 '17: 0.00 Q1 '18: 0.00 Q2 '18: 0.00 Q3 '18: 0.00 Q4 '18: 0.00 Q1 '19: 0.00 Q2 '19: 0.00 Q3 '19: 0.00 Q4 '19: 0.00 Q1 '20: 0.00 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '21: -0.02 Q3 '21: -0.07 Q4 '21: -0.14 Q2 '23: -0.25 Q3 '23: -0.21 Q4 '23: -0.15 Q1 '24: -0.08 Q2 '24: -0.03 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.00 Q2 '25: 0.00 Q3 '25: 0.00 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.